Company Resverlogix Corp.

Stocks

RVX

CA76128M1086

Biotechnology & Medical Research

Market Closed - Toronto S.E. 15:46:52 2026-09-04 EDT			5-day change	1st Jan Change
0.0950 ^CAD	-5.00%		0.00%	-5.00%

08-14	Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-25	Resverlogix Corp. - Shareholder/Analyst Call

Business description: Resverlogix Corp.

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Sales by Activity: Resverlogix Corp.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all business segments

Geographical breakdown of sales: Resverlogix Corp.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)

See all geographic segments

Executive Committee: Resverlogix Corp.

Manager	Title	Age	Since
Donald McCaffrey CEO	Chief Executive Officer	-	2003-04-24
Anthony Cann DFI	Director of Finance/CFO	78	2009-10-28
Ewelina Kulikowski CTO	Chief Tech/Sci/R&D Officer	-	2022-08-14
Michael Sweeney CTO	Chief Tech/Sci/R&D Officer	65	2014-11-02

See RESVERLOGIX CORP. governance

Composition of the Board of Directors: Resverlogix Corp.

Director	Title	Age	Since
Donald McCaffrey CHM	Chairman	-	2016-04-03
Kelly McNeill BRD	Director/Board Member	56	2009-10-14
Kenneth Zuerblis BRD	Director/Board Member	66	2010-09-28
Siu Lun To BRD	Director/Board Member	57	2019-12-18
Bradley J Glass BRD	Director/Board Member	-	2025-11-17

Composition of the Board of Directors

Shareholders: Resverlogix Corp.

Name	Stocks	%	Valuation
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 24.8 %	85,286,524	24.8 %	6 M $
Donald McCaffrey 1.53 %	5,263,266	1.53 %	373 692 $
Anthony Cann 0.6055 %	2,082,255	0.6055 %	147 840 $
Michael Sweeney 0.0452 %	155,312	0.0452 %	11 027 $
Kenneth Zuerblis 0.0311 %	107,062	0.0311 %	7 601 $

List of RESVERLOGIX CORP. shareholders

Company details: Resverlogix Corp.

Resverlogix Corp.

4820 Richard Road SW

T3E 6L1, Calgary

+403 254 9252

http://www.resverlogix.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RESVERLOGIX CORP.	-5.00%	0.00%	-5.00%	+18.75%	23.64M
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+99.78%	67.98B
ARGENX SE	-2.89%	-0.87%	+33.87%	+81.14%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+377.83%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-13.58%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-1.42%	-0.74%	+24.37%	+15.84%	25.74B
GENMAB A/S	-0.83%	+1.23%	+23.52%	-18.23%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+375.70%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.20%	-1.37%	-6.86%	+549.54%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+165.57%	14.62B
Average	-1.43%	+0.23%	+36.44%	+165.23%	27.91B
Weighted average by Cap.	-1.42%	+0.18%	+36.19%	+140.53%